Cipher Pharmaceuticals Inc. said Bausch Health Cos Inc. is terminating their partnership for constipation drug Trulance, citing breach of the agreement's certain provisions.
Oakville, Ontario-based Cipher acquired the exclusive Canadian marketing and selling rights to Trulance from Synergy Pharmaceuticals Inc. in February 2018. Bausch Health then bought certain assets of Synergy Pharmaceuticals in March 2019, including Trulance.
Trulance is approved by the U.S. Food and Drug Administration to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation.
As part of a strategic review process for its Canadian commercial assets, Cipher was negotiating the sublicensing of Trulance with multiple parties.
Cipher said the termination is without merit and plans on challenging it.